Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
BioPharma Dive21h
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
FierceBiotech1d
Sanofi shows how $500M bowel disease bet compares to Merck and Roche's rival assets
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...
pharmaphorum4d
The rise and market race of anti-IL23p19 therapies in IBD: How ECCO 2025 readouts will shape the anti-interleukin landscape
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
PharmiWeb5d
Cystic Fibrosis Market: Trends, Insights, and Growth Projections 2025-2035
The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...
Pharmaceutical Technology6d
New CEOs to join Merck KGaA’s executive board
E. Merck KG board of partners has announced the appointment of new CEOs to Merck KGaA’s executive board, aiding its ongoing ...